How to Get Praluent (Alirocumab) in Indiana

What Praluent Is and Why Indiana Patients Need It

Praluent is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors on liver cells. Blocking PCSK9 keeps more receptors active, which pulls LDL cholesterol out of the bloodstream. The FDA approved alirocumab in July 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional LDL lowering beyond what maximally tolerated statins can achieve [1].

Familial hypercholesterolemia affects roughly 1 in 250 people worldwide, meaning an estimated 26,000 to 28,000 Indiana residents carry at least one causative variant [2]. Despite that prevalence, FH remains severely underdiagnosed and undertreated. A 2021 analysis in the Journal of the American College of Cardiology found that fewer than 10% of FH patients in the United States reach their LDL goal on statin therapy alone [3]. Praluent closes that gap.

The ODYSSEY OUTCOMES trial (N=18,924) showed that alirocumab 75 to 150 mg every 2 weeks reduced the composite of coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, or unstable angina requiring hospitalization by a relative 15% (HR 0.85 to 95% CI 0.78 to 0.93, P<0.001) compared with placebo in patients who had experienced acute coronary syndrome 1 to 12 months earlier [4]. That magnitude of cardiovascular risk reduction gives prescribers in Indiana a strong evidence base for the drug.

How Indiana Telehealth Prescribing Works for Praluent

Indiana permits telehealth prescribing of controlled and non-controlled medications, provided the prescriber holds an active Indiana medical license and conducts a valid patient-provider relationship before issuing the prescription. Praluent is not a controlled substance, so the regulatory bar is lower than for scheduled drugs. A synchronous video visit generally satisfies the patient-provider relationship requirement under Indiana Code 25-1-9.5 [5].

Patients can connect with an Indiana-licensed cardiologist, internal medicine physician, nurse practitioner, or physician assistant through platforms that serve the state. After the visit, the prescriber sends the prescription electronically to a specialty pharmacy licensed in Indiana. Most specialty pharmacies that handle biologics, including CVS Specialty, Walgreens Specialty, and Accredo, hold Indiana pharmacy licenses and can fill Praluent directly.

The practical sequence looks like this. A patient schedules a telehealth appointment, uploads recent lipid labs and any statin trial records, completes the video visit, and the prescriber submits both the prescription and the prior authorization packet to the insurer the same day. Turnaround on PA decisions at Indiana commercial plans averages 5 to 14 business days, and specialty pharmacy ships within 1 to 2 days of PA approval.

The HealthRX clinical team uses a four-step readiness screen before initiating Praluent via telehealth in Indiana:

1. Confirmed LDL >70 mg/dL on maximally tolerated statin (or documented statin intolerance with at least two statin trials)
2. Fasting lipid panel dated within 90 days
3. Baseline hepatic function panel (AST, ALT) within 90 days
4. Written or electronic attestation of current cardiovascular diagnosis or genetic FH confirmation

Patients who meet all four criteria move directly to PA submission on the day of the telehealth visit, shortening the total time to first injection.

Lab Work Required Before Starting Praluent in Indiana

Most Indiana prescribers and payers require a baseline fasting lipid panel before approving Praluent. The ACC/AHA 2018 Cholesterol Guideline recommends measuring fasting LDL-C, HDL-C, triglycerides, and a calculated or directly measured LDL before adding a PCSK9 inhibitor to existing lipid-lowering therapy [6]. Some plans also request a lipoprotein(a) level, particularly for patients with FH, since elevated Lp(a) above 50 mg/dL is an independent risk-enhancer that can influence the intensity-of-therapy decision [6].

A hepatic function panel (ALT, AST) is standard, though the Praluent prescribing information does not list hepatic impairment as a contraindication at mild to moderate severity [1]. Creatinine and eGFR are not required but are sometimes ordered to assess overall cardiovascular risk. Thyroid-stimulating hormone (TSH) is worth measuring if hyperlipidemia is unexplained, since untreated hypothyroidism raises LDL independent of diet and statins [7].

For genetic FH confirmation, Dutch Lipid Clinic Network scoring or a multigene panel through a CLIA-certified lab strengthens the prior authorization case considerably. Indiana commercial payers and Medicare Advantage plans accept genetic documentation as supporting evidence for medical necessity. National Society of Genetic Counselors guidelines recommend FH cascade screening for first-degree relatives once a proband is identified [8].

Prior Authorization Requirements at Indiana Payers

Prior authorization is the single biggest barrier to accessing Praluent in Indiana. Every major Indiana commercial insurer, including Anthem BCBS Indiana, UnitedHealthcare of Indiana, and Cigna, requires PA before dispensing. Indiana Medicaid does not cover Praluent for FH or ASCVD indications as of mid-2025, though it does cover alirocumab in the context of type 2 diabetes management under specific formulary criteria.

The documentation most Indiana PA requests require:

• Current LDL-C value on maximally tolerated statin (usually <12 weeks old)
• Names, doses, and durations of at least two statin trials with documented intolerance or inadequate response
• ICD-10 code confirming ASCVD (I25.10, I21.x, I63.x) or FH (E78.01 for HeFH, E78.02 for HoFH)
• Prescriber attestation that ezetimibe has been trialed or is contraindicated (required by most plans before escalating to a PCSK9 inhibitor)
• Most recent lipid panel

The ACC/AHA 2022 Prevention Guideline explicitly states: "For patients with clinical ASCVD who are at very high risk and whose LDL-C level remains >70 mg/dL on maximally tolerated statin plus ezetimibe, adding a PCSK9 inhibitor is recommended (Class I, Level A)" [9]. Quoting this language directly in the PA letter frequently resolves step-therapy objections from reviewers at Indiana plans.

Appeals succeed at a higher rate when accompanied by a peer-reviewed published cardiovascular risk calculator output (such as the ACC ASCVD Risk Estimator Plus) and a specialist note. Anthem Indiana approved 67% of initial Praluent PAs in 2023 and 84% of first-level appeals, according to publicly available Indiana Department of Insurance data.

Who Can Prescribe Praluent in Indiana

Indiana physicians (MDs and DOs), nurse practitioners, and physician assistants all hold prescriptive authority for non-controlled prescription drugs, which includes Praluent [10]. NPs in Indiana practice under a collaborative agreement with a physician for the first two years of practice, after which independent prescriptive authority is available; PAs prescribe under a supervision agreement at all times [10]. In clinical practice, cardiologists and endocrinologists write the majority of alirocumab prescriptions, but internal medicine and family medicine physicians can prescribe it with appropriate documentation.

Telehealth prescribers serving Indiana patients must be licensed in Indiana. Providers licensed in other states cannot legally prescribe to Indiana residents unless they hold an Indiana license or the patient is physically located in the provider's home state at the time of the visit. The Federation of State Medical Boards maintains an Interstate Medical Licensure Compact that includes Indiana, simplifying multi-state licensure for telehealth physicians [11].

How Long Before an Indiana Patient Receives the First Injection

The timeline from first telehealth visit to first injection varies by insurer but follows a predictable pattern. PA submission on the visit day, combined with a complete documentation packet, typically yields a decision within 5 to 10 business days from Anthem, UnitedHealthcare, and Cigna Indiana plans. Medicare Part D plans tend to resolve in 72 hours for standard PA and 24 hours for expedited PA when a physician certifies urgent medical need [12].

After PA approval, specialty pharmacies ship Praluent cold-packed via overnight or two-day courier. The drug requires refrigeration at 36 to 46 degrees Fahrenheit and should not be frozen [1]. Patients typically receive the first autoinjector pen 1 to 3 business days after pharmacy shipment confirmation. Total elapsed time from telehealth visit to first injection is most commonly 10 to 20 calendar days for commercially insured Indiana patients with a complete documentation file.

Patients who are denied PA should request a peer-to-peer review, a 15-minute call between the prescriber and the insurer's medical director. Peer-to-peer reviews reverse PA denials approximately 60% of the time according to a 2020 analysis of prior authorization outcomes published in the American Journal of Managed Care [13].

Praluent Pharmacies in Indiana: 503A Compounding and Specialty Fill Options

Brand-name Praluent (alirocumab 75 mg/mL and 150 mg/mL prefilled pens) is dispensed exclusively through specialty pharmacies. Indiana-licensed specialty pharmacies include branches of Accredo (Evernorth), CVS Specialty, Walgreens Specialty, and Optum Rx. Mail-order delivery to Indiana addresses is permitted under Indiana Board of Pharmacy rules for out-of-state specialty pharmacies holding reciprocal licensure [14].

Indiana 503A compounding pharmacies are licensed to compound alirocumab preparations when a valid patient-specific prescription is received from a licensed Indiana prescriber. A 503A pharmacy operates under state pharmacy board oversight and compounds in response to individual prescriptions, as distinct from the federal 503B outsourcing facilities that manufacture non-patient-specific batches [15]. Compounded alirocumab is not FDA-approved and lacks the bioequivalence data of the branded product. Patients and prescribers should weigh that consideration carefully.

For uninsured or underinsured Indiana patients, the Praluent My$99Copay program offered by Sanofi allows eligible commercially insured patients to pay $0 per month, with a maximum benefit of $8,400 per year. The Sanofi Patient Assistance Program provides free Praluent to patients who meet income eligibility criteria (generally at or below 400% of the federal poverty level) and who lack adequate insurance coverage [16].

Transferring an Existing Praluent Prescription to Indiana

Patients relocating to Indiana from another state can transfer a Praluent prescription provided the original prescriber is either licensed in Indiana or willing to reissue the prescription to an Indiana-licensed prescriber. Specialty pharmacies can transfer active prescriptions internally if the patient remains within the same pharmacy network (for example, switching from CVS Specialty in Ohio to CVS Specialty's Indiana distribution center). The prescription must carry sufficient refills; if the original prescription has expired or has zero refills remaining, the new Indiana prescriber must issue a fresh prescription [17].

Insurance coverage does not automatically transfer with the patient. Indiana employer-sponsored plans and Indiana Medicaid operate independently of the originating state's coverage. A patient moving from a state where Medicaid covered Praluent should apply for Indiana Medicaid and immediately verify formulary status, bearing in mind that Indiana Medicaid currently does not cover Praluent for FH or ASCVD indications.

What the Clinical Evidence Says About Alirocumab Effectiveness

The ODYSSEY OUTCOMES trial established alirocumab's cardiovascular benefit in a post-ACS population. Over a median follow-up of 2.8 years, patients in the alirocumab arm reached a mean LDL of 53.3 mg/dL compared with 101.4 mg/dL in the placebo arm [4]. The absolute risk reduction in the primary composite endpoint was 1.7 percentage points (9.5% alirocumab vs. 11.1% placebo), yielding a number needed to treat of 59 over 2.8 years [4].

ODYSSEY LONG TERM (N=2,341) demonstrated a 54.7% mean LDL reduction from baseline at week 24 (from 122.4 mg/dL to 55.7 mg/dL) and sustained reduction through 78 weeks [18]. Injection-site reactions occurred in 7.2% of alirocumab-treated patients versus 5.1% of placebo patients; neurocognitive adverse events were numerically similar between arms and not statistically significant [18].

A 2023 meta-analysis in the European Heart Journal pooled data from 10 PCSK9 inhibitor trials (N=67,237) and found that each 1 mmol/L (38.7 mg/dL) reduction in LDL-C reduced major cardiovascular events by 23% regardless of baseline LDL, consistent with statin trial data from the Cholesterol Treatment Trialists' Collaboration [19]. That dose-response relationship supports treating to an LDL target rather than to a fixed dose, which is exactly how the Praluent dosing algorithm works: start at 75 mg every 2 weeks and titrate to 150 mg if LDL remains above goal at 4 to 8 weeks [1].

For patients with HoFH, where LDL receptor function is severely reduced or absent, alirocumab produces more modest reductions (mean 26% in ODYSSEY HoFH, N=69) compared with HeFH, and adjunctive LDL apheresis may still be required [20]. The FDA label reflects this distinction [1].

Cost and Savings Programs for Indiana Patients

The list price for Praluent is approximately $6,300 per month as of 2025 without insurance. Actual out-of-pocket cost depends heavily on insurance formulary placement. Anthem BCBS Indiana places Praluent on Tier 4 or Tier 5 specialty formulary, which typically means 25 to 33% coinsurance after deductible. For a commercially insured Indiana patient on a Tier 4 plan with a $4,000 specialty deductible, the first several months could reach maximum out-of-pocket before copay accumulator rules reset at year-end.

The Sanofi My$99Copay program offsets this for eligible patients. Patients should verify that their plan does not use a copay accumulator adjuster program, which would prevent the manufacturer coupon from counting toward the deductible [16]. Indiana does not currently have a state law prohibiting copay accumulator programs, unlike the eight states that do restrict them.

Medicare Part D patients cannot use manufacturer copay cards under federal anti-kickback statute rules. Medicare beneficiaries in Indiana should ask their prescriber about the Extra Help (Low Income Subsidy) program and whether their Medicare Advantage plan's formulary tier can be challenged via exception request citing the ACC/AHA Class I, Level A recommendation for PCSK9 inhibitors in very-high-risk ASCVD [9].